Treatment

KJ-103 clinical trials

1 indexed studies · 0 currently recruiting

Not yet recruitingPhase I/II
A Phase I/IIa trial of KJ-103 in solid cancers
This study is testing a new drug called KJ-103 for advanced cancers. Researchers want to find the safest dose and see if it helps fight cancer, either alone or with another treatment called pembrolizumab. It's the first time KJ-103 is being given to people.
For: Advanced solid tumour types which are known to have a high frequency of TROP2 positivity (e.g., head and neck squamous cell carcinoma [HNSCC], urothelial, breast cancer, non-small cell lung cancer [NSCLC])
United Kingdom · England